| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 04/06/2024 | 22:57 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:FLGT | Fulgent Genetics Inc |
| 03/06/2024 | 14:00 | Business Wire | Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer | NASDAQ:FLGT | Fulgent Genetics Inc |
| 24/05/2024 | 14:00 | Business Wire | Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting | NASDAQ:FLGT | Fulgent Genetics Inc |
| 16/05/2024 | 22:29 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:FLGT | Fulgent Genetics Inc |
| 14/05/2024 | 22:05 | Business Wire | Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics | NASDAQ:FLGT | Fulgent Genetics Inc |
| 03/05/2024 | 13:00 | Business Wire | Fulgent Reports First Quarter 2024 Financial Results | NASDAQ:FLGT | Fulgent Genetics Inc |
| 11/04/2024 | 22:05 | Business Wire | Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024 | NASDAQ:FLGT | Fulgent Genetics Inc |
| 28/02/2024 | 13:00 | Business Wire | Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results | NASDAQ:FLGT | Fulgent Genetics Inc |
| 13/02/2024 | 14:00 | Business Wire | Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024 | NASDAQ:FLGT | Fulgent Genetics Inc |
| 10/02/2024 | 00:09 | Edgar (US Regulatory) | Form 5 - Annual statement of changes in beneficial ownership of securities | NASDAQ:FLGT | Fulgent Genetics Inc |
| 09/02/2024 | 14:31 | PR Newswire (US) | Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic Testing | NASDAQ:FLGT | Fulgent Genetics Inc |
| 13/12/2023 | 03:43 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:FLGT | Fulgent Genetics Inc |
| 14/11/2023 | 22:30 | Business Wire | Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference | NASDAQ:FLGT | Fulgent Genetics Inc |
| 03/11/2023 | 21:05 | Business Wire | Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting | NASDAQ:FLGT | Fulgent Genetics Inc |
| 03/11/2023 | 12:31 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:FLGT | Fulgent Genetics Inc |
| 03/11/2023 | 12:00 | Business Wire | Fulgent Reports Third Quarter 2023 Financial Results | NASDAQ:FLGT | Fulgent Genetics Inc |
| 25/10/2023 | 14:00 | Business Wire | Fulgent Announces Two Poster Presentations at SITC 2023 Annual Meeting | NASDAQ:FLGT | Fulgent Genetics Inc |
| 17/10/2023 | 14:00 | Business Wire | Fulgent Genetics to Announce Third Quarter 2023 Financial Results on Friday November 3, 2023 | NASDAQ:FLGT | Fulgent Genetics Inc |
| 04/08/2023 | 13:00 | Business Wire | Fulgent Reports Second Quarter 2023 Financial Results | NASDAQ:FLGT | Fulgent Genetics Inc |
| 24/07/2023 | 22:05 | GlobeNewswire Inc. | Exagen Inc. Appoints Paul Kim to Board of Directors | NASDAQ:FLGT | Fulgent Genetics Inc |
| 18/07/2023 | 14:00 | Business Wire | Fulgent Genetics to Announce Second Quarter 2023 Financial Results on Friday, August 4, 2023 | NASDAQ:FLGT | Fulgent Genetics Inc |
| 06/06/2023 | 23:07 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:FLGT | Fulgent Genetics Inc |
| 05/06/2023 | 14:30 | Business Wire | Fulgent Data at ASCO 2023 Highlights Progress for Its Lead Therapeutic Oncology Candidate, FID-007, in Various Cancers | NASDAQ:FLGT | Fulgent Genetics Inc |
| 18/05/2023 | 22:59 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) | NASDAQ:FLGT | Fulgent Genetics Inc |
| 18/05/2023 | 22:07 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:FLGT | Fulgent Genetics Inc |
| 18/05/2023 | 22:05 | Business Wire | Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2023 Annual Meeting | NASDAQ:FLGT | Fulgent Genetics Inc |
| 05/05/2023 | 13:00 | Business Wire | Fulgent Reports First Quarter 2023 Financial Results | NASDAQ:FLGT | Fulgent Genetics Inc |
| 20/04/2023 | 22:05 | Business Wire | Fulgent Genetics to Announce First Quarter 2023 Financial Results on Friday May 5, 2023 | NASDAQ:FLGT | Fulgent Genetics Inc |
| 11/04/2023 | 14:00 | PR Newswire (US) | Mission Bio Partners with Fulgent Genetics to Broaden Accessibility of Single-Cell Multi-Omics for Drug Development and Clinical Research | NASDAQ:FLGT | Fulgent Genetics Inc |
| 03/04/2023 | 12:17 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) | NASDAQ:FLGT | Fulgent Genetics Inc |